BioCentury
ARTICLE | Company News

Medivir, Daewoong Pharmaceutical deal

September 16, 2013 7:00 AM UTC

Medivir said it and Daewoong agreed to discontinue development of MIV-210 to treat HBV infection. Medivir said that although MIV-210 has a "proven competitive antiviral effect," it does not remove the...